Ostarine (MK-2866 / enobosarm)

The dominant downside for ostarine is a real, intrinsic set of harms, not an absence of data. The drug causes cholestatic liver injury, suppresses the hormonal axis and lowers HDL, and these signals appear even in short, low-dose trials rather than only in gray-market misuse.

The severity gradient is where sourcing and dose take over. The worst liver cases sit at recreational doses of 10 to 30 mg, often stacked and used far longer than any studied protocol, and only about half of internet SARM products contain what the label claims.

Safety sits at 3.8, just below the catastrophic floor, because the documented cases recovered rather than proving permanent or fatal, and the severe injuries concentrate at unstudied doses. The dimensions below keep safety high while placing dependency and reversibility in the middle.

Safety Risk (3.8/5.0): Ostarine has a real intrinsic harm signal that keeps safety high without crossing the 4.0 catastrophic floor. LiverTox rates SARMs a likelihood-B probable cause of clinically apparent liver injury, with case reports of bilirubin peaks of 20 to 40 and transplant evaluation before recovery (LiverTox 2023).

Alongside the liver signal, trial and review data show testosterone and HDL suppression even at 1 to 3 mg, so the hormonal and cardiovascular risks are intrinsic, not incidental (Vignali et al. 2023).

It sits at 3.8 rather than higher because the documented liver cases recovered over 1 to 6 months, the cholestatic pattern is partly dose-related, and the severe events concentrate at recreational 10 to 30 mg doses that run 3 to 10 times anything studied. Those doses escalate the liver risk sharply.

Side Effect Profile (2.6/5.0): At the 1 to 3 mg trial doses, ostarine was tolerated with no serious hepatic events reported, and the common complaints were mild lethargy and measurable shifts in bloodwork.

The realistic profile at higher doses is worse: falling testosterone, suppressed libido, a measurable HDL drop, and liver-enzyme flags that in some case reports reached the emergency room, especially when stacked with other compounds (Vignali et al. 2023).

The score reflects a mild profile at studied doses that turns more concerning as the dose climbs into the unstudied range most users take.

Financial Cost (2.5/5.0): There is no legitimate channel to price, because ostarine is neither an approved drug nor a lawful supplement. The only route is a research-chemical vendor selling capsules or liquid for laboratory use.

A monthly recreational supply is inexpensive by pharmaceutical standards, which lands cost in the mid-range, but the buyer pays an ordinary price for a product with no manufacturing oversight and no guarantee it contains what the label claims (Van Wagoner et al. 2017).

Time and Effort Burden (2.0/5.0): A once-daily oral dose is a light schedule to administer. The burden sits in the surrounding work rather than the pill.

Doing it responsibly means baseline and follow-up bloodwork, a post-cycle protocol to manage suppression, and sourcing a product that no approved supply chain stands behind. That adds a real, if modest, effort surface a labeled medicine would not.

Opportunity Cost (2.4/5.0): For muscle and body composition, ostarine competes with better-evidenced, lower-risk options, from resistance training and protein to medically supervised testosterone for those who qualify.

Choosing an unapproved compound with an intrinsic liver signal over those means accepting real risk for a modest gain, which is a meaningful opportunity cost even though ostarine does not physically block other efforts. The score reflects the presence of safer, established routes to the same goal.

Dependency and Withdrawal (2.6/5.0): Ostarine is not addictive in the craving sense, but it creates a real functional dependency through hormonal suppression. Stopping leaves the axis suppressed until it recovers, which is why users run post-cycle protocols.

That recovery is expected but not well quantified for ostarine, and the loss of muscle on stopping is a durability matter scored above. The dependency score reflects the axis-suppression burden that stopping imposes, which is more than a simple metabolic compound but less than an addictive drug.

Reversibility (1.8/5.0): The drug itself clears cleanly, since ostarine has a short pharmacokinetic footprint and washes out after the last dose with no permanent structural change described.

The hormonal recovery that needs a post-cycle protocol is routed to dependency, scored above, rather than counted here, per the scoring convention that keeps a single harm from being double-counted.

On the narrow question this dimension asks, whether the compound leaves the body cleanly, ostarine does, which places reversibility near the floor with the caveat that clean washout is inferred from its pharmacokinetics rather than measured with a durability follow-up.